BCR-ABL 926-934 (HLA-A*02:01)
( SSKALQRPV )
In chronic myelogenous leukemia, a translocation occurs between chromosomes 9 and 22, which leads to a BCR-ABL fusion gene. This results in chimeric proteins.
The nonapeptide BCR-ABL 926-934 (epitope ID 2187155) with the amino acid sequence SSKALQRPV from the junctional region of the BCR-ABLb3a2 molecule has been shown to be immunogenic. It could therefore be useful for developing a specific immunotherapy for patients with chronic myelogenous leukemia.
BCR-ABL 926-934 binds to HLA-A2.1 molecules and triggers primary reactions of cytotoxic T lymphocytes in vitro.
| Sequence: | SSKALQRPV | |
| Gene: | BCR | |
| Delivery: | 3 weeks | |
| C-Terminus: | OH | |
| N-Terminus: | H | |
| Amount: | 1 mg | |
| Counter Ion: | TFA | |
| Protein: | Human Bcr-abl 210 kD fusion protein | |
| Species: | Human | |
| Allele: | HLA-A*02:01 | |
| Application : | Flow Cytometry | |
| Indication : | Cancer | |
| Purity : | 95% HPLC-MS |
Protocols and Tips
Data sheets
Safety data sheet poly peptides:
Yotnda, P et al. “Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.” The Journal of clinical investigation vol. 101,10 (1998): 2290-6. doi:10.1172/JCI488
€63.50*
Available, delivery time: 3-4 weeks
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
Product number:
EP12190_1